Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Sydes, M.R., Spears, M.R., Mason, M.D., Clarke, N.W., Dearnaley, D.P., de Bono, J.S., Attard, G., Chowdhury, S., Cross, W., Gillessen, S., et al. (2018). Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann oncol, Vol.29 (5), pp. 1235-1248.  show abstract

Gillessen, S., Attard, G., Beer, T.M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B.H., Clarke, N., et al. (2018). Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur urol, Vol.73 (2), pp. 178-211.  show abstract

Prekovic, S., Van den Broeck, T., Moris, L., Smeets, E., Claessens, F., Joniau, S., Helsen, C. & Attard, G. (2018). Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. Mol cell endocrinol, Vol.462 (Pt A), pp. 56-63.  show abstract

Linch, M., Goh, G., Hiley, C., Shanmugabavan, Y., McGranahan, N., Rowan, A., Wong, Y.N., King, H., Furness, A., Freeman, A., et al. (2017). Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Ann oncol, Vol.28 (10), pp. 2472-2480.  show abstract

Pezaro, C.J., Omlin, A., Mastris, K., ANZUP Consumer Advisory Panel, , Attard, G., Beer, T.M., Chi, K.N., Chowdhury, S., Davis, I.D., Drake, C.G., et al. (2017). Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Ann oncol, Vol.28 (8), pp. 1692-1694.

Conteduca, V., Wetterskog, D., Sharabiani, M.T., Grande, E., Fernandez-Perez, M.P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., et al. (2017). Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann oncol, Vol.28 (7), pp. 1508-1516.  show abstract

Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C.J., Petrylak, D.P., et al. (2017). Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Ann oncol, Vol.28 (1), pp. 90-95.  show abstract

Patrikidou, A., Uccello, M., Tree, A., Parker, C., Attard, G., Eeles, R., Khoo, V., van As, N., Huddart, R., Dearnaley, D., et al. (2017). Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer. Clin oncol (r coll radiol), Vol.29 (10), pp. e174-e175.

Mason, M.D., Clarke, N.W., James, N.D., Dearnaley, D.P., Spears, M.R., Ritchie, A.W., Attard, G., Cross, W., Jones, R.J., Parker, C.C., et al. (2017). Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. J clin oncol, Vol.35 (14), pp. 1530-1541.  show abstract

McDaniel, A.S., Ferraldeschi, R., Krupa, R., Landers, M., Graf, R., Louw, J., Jendrisak, A., Bales, N., Marrinucci, D., Zafeiriou, Z., et al. (2017). Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. Bju int, Vol.120 (5B), pp. E30-E44.  show abstract

James, N.D., de Bono, J.S., Spears, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Ritchie, A.W., Amos, C.L., Gilson, C., Jones, R.J., et al. (2017). Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N engl j med, Vol.377 (4), pp. 338-351.  show abstract

Ferraldeschi, R., Welti, J., Powers, M.V., Yuan, W., Smyth, T., Seed, G., Riisnaes, R., Hedayat, S., Wang, H., Crespo, M., et al. (2016). Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. Cancer res, Vol.76 (9), pp. 2731-2742.  show abstract

Attard, G., Parker, C., Eeles, R.A., Schroder, F., Tomlins, S.A., Tannock, I., Drake, C.G. & de Bono, J.S. (2016). Prostate cancer. Lancet, Vol.387 (10013), pp. 70-82.

Attard, G., Parker, C., Eeles, R.A., Schröder, F., Tomlins, S.A., Tannock, I., Drake, C.G. & de Bono, J.S. (2016). Prostate cancer. Lancet, Vol.387 (10013), pp. 70-82.  show abstract

James, N.D., Spears, M.R., Clarke, N.W., Dearnaley, D.P., Mason, M.D., Parker, C.C., Ritchie, A.W., Russell, J.M., Schiavone, F., Attard, G., et al. (2016). Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. Jama oncol, Vol.2 (3), pp. 348-357.  show abstract

Jayaram, A. & Attard, G. (2016). Diagnostic Gleason score and castration-resistant prostate cancer. Ann oncol, Vol.27 (6), pp. 962-964.

Rescigno, P., Lorente, D., Bianchini, D., Ferraldeschi, R., Kolinsky, M.P., Sideris, S., Zafeiriou, Z., Sumanasuriya, S., Smith, A.D., Mehra, N., et al. (2016). Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur urol, Vol.70 (5), pp. 724-731.  show abstract

Attard, G. & Antonarakis, E.S. (2016). Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide. Nat rev urol, Vol.13 (12), pp. 697-698.

Lorente, D., Omlin, A., Zafeiriou, Z., Nava-Rodrigues, D., Pérez-López, R., Pezaro, C., Mehra, N., Sheridan, E., Figueiredo, I., Riisnaes, R., et al. (2016). Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. Clin genitourin cancer, Vol.14 (6), pp. 485-493.  show abstract

James, N.D., Sydes, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Spears, M.R., Ritchie, A.W., Parker, C.C., Russell, J.M., Attard, G., et al. (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet, Vol.387 (10024), pp. 1163-1177.  show abstract

Salvi, S., Casadio, V., Conteduca, V., Lolli, C., Gurioli, G., Martignano, F., Schepisi, G., Testoni, S., Scarpi, E., Amadori, D., et al. (2016). Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget, Vol.7 (25), pp. 37839-37845.  show abstract

Beltran, H., Antonarakis, E.S., Morris, M.J. & Attard, G. (2016). Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. Am soc clin oncol educ book, Vol.35, pp. 131-141.  show abstract

Attard, G., de Bono, J.S., Logothetis, C.J., Fizazi, K., Mukherjee, S.D., Joshua, A.M., Schrijvers, D., van den Eertwegh, A.J., Li, W., Molina, A., et al. (2015). Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin cancer res, Vol.21 (7), pp. 1621-1627.  show abstract

Grist, E., de Bono, J.S. & Attard, G. (2015). Targeting extra-gonadal androgens in castration-resistant prostate cancer. J steroid biochem mol biol, Vol.145, pp. 157-163.  show abstract

Ferraldeschi, R., Welti, J., Luo, J., Attard, G. & de Bono, J.S. (2015). Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene, Vol.34 (14), pp. 1745-1757.  show abstract

Romanel, A., Gasi Tandefelt, D., Conteduca, V., Jayaram, A., Casiraghi, N., Wetterskog, D., Salvi, S., Amadori, D., Zafeiriou, Z., Rescigno, P., et al. (2015). Plasma AR and abiraterone-resistant prostate cancer. Sci transl med, Vol.7 (312), p. 312re10.  show abstract

Lee, C.P., Taylor, N.J., Attard, G., Pacey, S., Nathan, P.D., de Bono, J.S., Temple, G., Bell, S., Stefanic, M., Stopfer, P., et al. (2015). Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors. Oncologist, Vol.20 (4), pp. 368-369.  show abstract

Pezaro, C., Omlin, A., Perez-Lopez, R., Mukherji, D., Attard, G., Bianchini, D., Lorente, D., Parker, C., Dearnaley, D., de Bono, J.S., et al. (2015). Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. Clin radiol, Vol.70 (4), pp. 359-365.  show abstract

Ferraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015). PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur urol, Vol.67 (4), pp. 795-802.  show abstract

Rodrigues, D.N., Hazell, S., Miranda, S., Crespo, M., Fisher, C., de Bono, J.S. & Attard, G. (2015). Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin. Histopathology, Vol.66 (6), pp. 898-901.

Lorente, D., Mateo, J., Perez-Lopez, R., de Bono, J.S. & Attard, G. (2015). Sequencing of agents in castration-resistant prostate cancer. Lancet oncol, Vol.16 (6), pp. e279-e292.  show abstract

Grist, E. & Attard, G. (2015). The development of abiraterone acetate for castration-resistant prostate cancer. Urol oncol, Vol.33 (6), pp. 289-294.  show abstract

Jayaram, A. & Attard, G. (2015). Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer. Nat rev urol, Vol.12 (6), pp. 312-313.

Attard, G. & Beltran, H. (2015). Prioritizing precision medicine for prostate cancer. Ann oncol, Vol.26 (6), pp. 1041-1042.

Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., et al. (2015). Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann oncol, Vol.26 (8), pp. 1589-1604.  show abstract

Salvi, S., Casadio, V., Conteduca, V., Burgio, S.L., Menna, C., Bianchi, E., Rossi, L., Carretta, E., Masini, C., Amadori, D., et al. (2015). Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br j cancer, Vol.112 (10), pp. 1717-1724.  show abstract

Frenel, J.S., Carreira, S., Goodall, J., Roda, D., Perez-Lopez, R., Tunariu, N., Riisnaes, R., Miranda, S., Figueiredo, I., Nava-Rodrigues, D., et al. (2015). Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin cancer res, Vol.21 (20), pp. 4586-4596.  show abstract

Robinson, D., Van Allen, E.M., Wu, Y.-., Schultz, N., Lonigro, R.J., Mosquera, J.-., Montgomery, B., Taplin, M.-., Pritchard, C.C., Attard, G., et al. (2015). Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, Vol.162 (2), p. 454.

Punnoose, E.A., Ferraldeschi, R., Szafer-Glusman, E., Tucker, E.K., Mohan, S., Flohr, P., Riisnaes, R., Miranda, S., Figueiredo, I., Rodrigues, D.N., et al. (2015). PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. Br j cancer, Vol.113 (8), pp. 1225-1233.  show abstract

Scher, H.I., Heller, G., Molina, A., Attard, G., Danila, D.C., Jia, X., Peng, W., Sandhu, S.K., Olmos, D., Riisnaes, R., et al. (2015). Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J clin oncol, Vol.33 (12), pp. 1348-1355.  show abstract

Robinson, D., Van Allen, E.M., Wu, Y.-., Schultz, N., Lonigro, R.J., Mosquera, J.-., Montgomery, B., Taplin, M.-., Pritchard, C.C., Attard, G., et al. (2015). Integrative clinical genomics of advanced prostate cancer. Cell, Vol.161 (5), pp. 1215-1228.  show abstract

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015). DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N engl j med, Vol.373 (18), pp. 1697-1708.  show abstract

Crespo, M., van Dalum, G., Ferraldeschi, R., Zafeiriou, Z., Sideris, S., Lorente, D., Bianchini, D., Rodrigues, D.N., Riisnaes, R., Miranda, S., et al. (2015). Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Br j cancer, Vol.112 (7), pp. 1166-1174.  show abstract

Templeton, A.J., Pezaro, C., Omlin, A., McNamara, M.G., Leibowitz-Amit, R., Vera-Badillo, F.E., Attard, G., de Bono, J.S., Tannock, I.F. & Amir, E., et al. (2014). Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer, Vol.120 (21), pp. 3346-3352.  show abstract

Bianchini, D., Lorente, D., Rodriguez-Vida, A., Omlin, A., Pezaro, C., Ferraldeschi, R., Zivi, A., Attard, G., Chowdhury, S. & de Bono, J.S., et al. (2014). Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur j cancer, Vol.50 (1), pp. 78-84.  show abstract

Pezaro, C., Omlin, A., Lorente, D., Rodrigues, D.N., Ferraldeschi, R., Bianchini, D., Mukherji, D., Riisnaes, R., Altavilla, A., Crespo, M., et al. (2014). Visceral disease in castration-resistant prostate cancer. Eur urol, Vol.65 (2), pp. 270-273.  show abstract

Leibowitz-Amit, R., Templeton, A.J., Omlin, A., Pezaro, C., Atenafu, E.G., Keizman, D., Vera-Badillo, F., Seah, J.-., Attard, G., Knox, J.J., et al. (2014). Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann oncol, Vol.25 (3), pp. 657-662.  show abstract

Lorente, D., Bianchini, D., Rodriguez-Vida, A., Omlin, A., Pezaro, C., Ferraldeschi, R., Zivi, A., Attard, G., Chowdhury, S. & De Bono, J.S., et al. (2014). Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. Eur j cancer, Vol.50 (5), pp. 1042-1043.

Graham, T.J., Box, G., Tunariu, N., Crespo, M., Spinks, T.J., Miranda, S., Attard, G., de Bono, J., Eccles, S.A., Davies, F.E., et al. (2014). Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. J natl cancer inst, Vol.106 (4), p. dju033.  show abstract

Attard, G. (2014). Anti-androgen monotherapy for metastatic prostate cancer. Lancet oncol, Vol.15 (6), pp. 543-544.

Wong, Y.N., Ferraldeschi, R., Attard, G. & de Bono, J. (2014). Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat rev clin oncol, Vol.11 (6), pp. 365-376.  show abstract

Ravi, P., Mateo, J., Lorente, D., Zafeiriou, Z., Altavilla, A., Ferraldeschi, R., Sideris, S., Grist, E., Smith, A., Wong, S., et al. (2014). External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. Eur urol, Vol.66 (1), pp. 8-11.  show abstract

Omlin, A., Pezaro, C.J., Zaidi, S., Lorente, D., Mukherji, D., Bianchini, D., Ferraldeschi, R., Sandhu, S., Dearnaley, D., Parker, C., et al. (2014). Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. Br j cancer, Vol.110 (1), pp. 267-268.

Lorente, D., Omlin, A., Ferraldeschi, R., Pezaro, C., Perez, R., Mateo, J., Altavilla, A., Zafeirou, Z., Tunariu, N., Parker, C., et al. (2014). Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br j cancer, Vol.111 (12), pp. 2248-2253.  show abstract

Pezaro, C.J., Omlin, A.G., Altavilla, A., Lorente, D., Ferraldeschi, R., Bianchini, D., Dearnaley, D., Parker, C., de Bono, J.S. & Attard, G., et al. (2014). Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur urol, Vol.66 (3), pp. 459-465.  show abstract

Attard, G., Sydes, M.R., Mason, M.D., Clarke, N.W., Aebersold, D., de Bono, J.S., Dearnaley, D.P., Parker, C.C., Ritchie, A.W., Russell, J.M., et al. (2014). Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur urol, Vol.66 (5), pp. 799-802.  show abstract

Carreira, S., Romanel, A., Goodall, J., Grist, E., Ferraldeschi, R., Miranda, S., Prandi, D., Lorente, D., Frenel, J.-., Pezaro, C., et al. (2014). Tumor clone dynamics in lethal prostate cancer. Sci transl med, Vol.6 (254), p. 254ra125.  show abstract

Ong, M., Carreira, S., Goodall, J., Mateo, J., Figueiredo, I., Rodrigues, D.N., Perkins, G., Seed, G., Yap, T.A., Attard, G., et al. (2014). Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br j cancer, Vol.111 (5), pp. 828-836.  show abstract

Ferraldeschi, R., Sharifi, N., Auchus, R.J. & Attard, G. (2013). Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin cancer res, Vol.19 (13), pp. 3353-3359.  show abstract

Attard, G. & Kaye, S.B. (2013). Identifying prognostic signatures in the blood of ovarian cancer patients. Gynecol oncol, Vol.128 (1), pp. 1-2.

Ferraldeschi, R., Attard, G. & de Bono, J.S. (2013). Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer. Clin chem, Vol.59 (1), pp. 75-84.  show abstract

Omlin, A., Pezaro, C.J., Zaidi, S., Lorente, D., Mukherji, D., Bianchini, D., Ferraldeschi, R., Sandhu, S., Dearnaley, D., Parker, C., et al. (2013). Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br j cancer, Vol.109 (5), pp. 1079-1084.  show abstract

Lim, A.C. & Attard, G. (2013). Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer. Curr drug targets, Vol.14 (4), pp. 408-419.  show abstract

Sandhu, S.K., Omlin, A., Hylands, L., Miranda, S., Barber, L.J., Riisnaes, R., Reid, A.H., Attard, G., Chen, L., Kozarewa, I., et al. (2013). Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann oncol, Vol.24 (5), pp. 1416-1418.

Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J.S., et al. (2013). Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann oncol, Vol.24 (7), pp. 1807-1812.  show abstract

Demichelis, F. & Attard, G. (2013). A step toward functionally characterized prostate cancer molecular subtypes. Nature medicine, Vol.19 (8), pp. 966-967.

Omlin, A., Pezaro, C., Mukherji, D., Mulick Cassidy, A., Sandhu, S., Bianchini, D., Olmos, D., Ferraldeschi, R., Maier, G., Thompson, E., et al. (2013). Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur urol, Vol.64 (2), pp. 300-306.  show abstract

Pia, A., Vignani, F., Attard, G., Tucci, M., Bironzo, P., Scagliotti, G., Arlt, W., Terzolo, M. & Berruti, A. (2013). Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer treatment reviews, Vol.39 (8), pp. 966-973.

Bianchini, D., Omlin, A., Pezaro, C., Lorente, D., Ferraldeschi, R., Mukherji, D., Crespo, M., Figueiredo, I., Miranda, S., Riisnaes, R., et al. (2013). First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br j cancer, Vol.109 (10), pp. 2579-2586.  show abstract

Pezaro, C., Mukherji, D., Tunariu, N., Cassidy, A.M., Omlin, A., Bianchini, D., Seed, G., Reid, A.H., Olmos, D., de Bono, J.S., et al. (2013). Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br j cancer, Vol.109 (2), pp. 325-331.  show abstract

Dearnaley, D.P., Ottensmeier, C., Attard, G. & Crabb, S. (2013). New horizons for prostate cancer: part 2. Trends in urology & men's health, , pp. Reports 1-3.

Ligthart, S.T., Coumans, F.A., Bidard, F.-., Simkens, L.H., Punt, C.J., de Groot, M.R., Attard, G., de Bono, J.S., Pierga, J.-. & Terstappen, L.W., et al. (2013). Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. Plos one, Vol.8 (6), p. e67148.  show abstract

Richards, J., Lim, A.C., Hay, C.W., Taylor, A.E., Wingate, A., Nowakowska, K., Pezaro, C., Carreira, S., Goodall, J., Arlt, W., et al. (2012). Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer res, Vol.72 (9), pp. 2176-2182.  show abstract

Attard, G., Reid, A.H., Auchus, R.J., Hughes, B.A., Cassidy, A.M., Thompson, E., Oommen, N.B., Folkerd, E., Dowsett, M., Arlt, W., et al. (2012). Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J clin endocrinol metab, Vol.97 (2), pp. 507-516.  show abstract

Bellmunt, J., Attard, G., Bahl, A., Huland, H., Klotz, L., Kuban, D., Oudard, S. & Watson, W. (2012). Advances in the management of high-risk localised and metastatic prostate cancer. Bju int, Vol.109 Suppl 2, pp. 8-13.  show abstract

Eichholz, A., Ferraldeschi, R., Attard, G. & de Bono, J.S. (2012). Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol cell endocrinol, Vol.360 (1-2), pp. 68-75.  show abstract

Reid, A.H., Attard, G., Brewer, D., Miranda, S., Riisnaes, R., Clark, J., Hylands, L., Merson, S., Vergis, R., Jameson, C., et al. (2012). Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod pathol, Vol.25 (6), pp. 902-910.  show abstract

Sandhu, S.K., Moreno, V., Wilding, G., Omlin, A., Schelman, W.R., Miranda, S., Riinaes, R., Hylands, L., Attard, G., Cassidy, A., et al. (2012). PHASE I STUDY OF A POLY(ADP)-RIBOSE POLYMERASE (PARP) INHIBITOR MK-4827 (MK) WITH ANTITUMOUR ACTIVITY IN SPORADIC CASTRATION RESISTANT PROSTATE CANCER (CRPC). Asia-pacific journal of clinical oncology, Vol.8, pp. 33-33.

Carden, C.P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, M.D., Clarke, P.A., et al. (2012). The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol cancer ther, Vol.11 (7), pp. 1609-1617.  show abstract

Reid, A.H., Attard, G., Brewer, D., Miranda, S., Riisnaes, R., Clark, J., Hylands, L., Merson, S., Vergis, R., Jameson, C., et al. (2012). Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod pathol, Vol.25 (8), p. 1179.

Nagy, D., Crespo, M., Attard, G., Miranda, S., Garsha, K., Sathyanarayana, U.G., Yun, S., Otter, M., Miller, P., Pestano, G., et al. (2012). Development of a molecular profiling assay for circulating tumor cells (CTCs) utilizing automated multiplexed in situ hybridization for metastatic castrate-resistant prostate cancer (mCRPC). Journal of clinical oncology, Vol.30 (5).

Mezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., et al. (2012). Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. Ann oncol, Vol.23 (11), pp. 2943-2947.  show abstract

Olmos, D., Brewer, D., Clark, J., Danila, D.C., Parker, C., Attard, G., Fleisher, M., Reid, A.H., Castro, E., Sandhu, S.K., et al. (2012). Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet oncol, Vol.13 (11), pp. 1114-1124.  show abstract

Pezaro, C. & Attard, G. (2012). Prostate cancer in 2011: redefining the therapeutic landscape for CRPC. Nat rev urol, Vol.9 (2), pp. 63-64.

Perkins, G., Yap, T.A., Pope, L., Cassidy, A.M., Dukes, J.P., Riisnaes, R., Massard, C., Cassier, P.A., Miranda, S., Clark, J., et al. (2012). Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. Plos one, Vol.7 (11), p. e47020.  show abstract

Attard, G., Crespo, M., Lim, A.C., Pope, L., Zivi, A. & de Bono, J.S. (2011). Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative--letter. Clin cancer res, Vol.17 (9), pp. 3048-3049.

Attard, G., Richards, J. & de Bono, J.S. (2011). New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin cancer res, Vol.17 (7), pp. 1649-1657.  show abstract

Messiou, C., Cook, G., Reid, A.H., Attard, G., Dearnaley, D., de Bono, J.S. & de Souza, N.M. (2011). The CT flare response of metastatic bone disease in prostate cancer. Acta radiol, Vol.52 (5), pp. 557-561.  show abstract

Attard, G. & de Bono, J.S. (2011). Utilizing circulating tumor cells: challenges and pitfalls. Curr opin genet dev, Vol.21 (1), pp. 50-58.  show abstract

Sonpavde, G., Attard, G., Bellmunt, J., Mason, M.D., Malavaud, B., Tombal, B. & Sternberg, C.N. (2011). The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur urol, Vol.60 (2), pp. 270-278.  show abstract

Olmos, D., Baird, R.D., Yap, T.A., Massard, C., Pope, L., Sandhu, S.K., Attard, G., Dukes, J., Papadatos-Pastos, D., Grainger, P., et al. (2011). Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clinical cancer research : an official journal of the american association for cancer research, Vol.17 (15), pp. 5188-5196.  show abstract

Ligthart, S.T., Coumans, F.A., Attard, G., de Bono, J.S. & Terstappen, L.W. (2011). Automated classification of circulating tumor cells optimized using clinical outcome of castration resistant prostate cancer patients. Cancer research, Vol.71.

Attard, G. & de Bono, J.S. (2011). Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin cancer res, Vol.17 (12), pp. 3867-3875.  show abstract

de Bono, J.S., Sandhu, S. & Attard, G. (2011). Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. Cancer cell, Vol.19 (5), pp. 573-574.

Olmos, D., Clark, J., Brewer, D., Barwell, L., Attard, G., Reid, A.H., Sandhu, S.K., Zivi, A., Bianchini, D., Oomen, N.B., et al. (2011). An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome. Journal of clinical oncology, Vol.29 (15).

Ligthart, S.T., Coumans, F.A., Attard, G., Cassidy, A.M., de Bono, J.S. & Terstappen, L.W. (2011). Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. Plos one, Vol.6 (11), p. e27419.  show abstract

Molife, L.R., Attard, G., Fong, P.C., Karavasilis, V., Reid, A.H., Patterson, S., Riggs, C.E., Higano, C., Stadler, W.M., McCulloch, W., et al. (2010). Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann oncol, Vol.21 (1), pp. 109-113.  show abstract

Carden, C.P., Sarker, D., Postel-Vinay, S., Yap, T.A., Attard, G., Banerji, U., Garrett, M.D., Thomas, G.V., Workman, P., Kaye, S.B., et al. (2010). Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug discov today, Vol.15 (3-4), pp. 88-97.  show abstract

Ligthart, S.T., Coumans, F.A., Attard, G., de Bono, J.S. & Terstappen, L.W. (2010). Automatic classification of EpCAM plus Cytokeratin plus objects versus survival in castration resistant prostate cancer. Cancer research, Vol.70.

Carden, C.P., Thavasu, P., Reid, A., Miranda, S., Crespo, M., Brown, R., Agarwal, R., Attard, G., de Bono, J.S., Kaye, S.B., et al. (2010). Correlation of elevated phosphorylated / total AKT ratio, chemoresistance and survival in ovarian cancer ascites samples. Cancer research, Vol.70.

Ligthart, S.T., Coumans, F.A., Attard, G., de Bono, J.S. & Terstappen, L.W. (2010). Automatic classification of EpCAM plus Cytokeratin plus objects versus survival in castration resistant prostate cancer. Cancer research, Vol.70.

Shan, L., Ambroisine, L., Clark, J., Yanez-Munoz, R.J., Fisher, G., Kudahetti, S.C., Yang, J., Kia, S., Mao, X., Fletcher, A., et al. (2010). The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer. Prostate cancer p d, Vol.13 (2), pp. 117-125.  show abstract

Coumans, F.A., Doggen, C.J., Attard, G., de Bono, J.S. & Terstappen, L.W. (2010). All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann oncol, Vol.21 (9), pp. 1851-1857.  show abstract

Attard, G., Reid, A.H. & de Bono, J.S. (2010). Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J clin oncol, Vol.28 (29), pp. e560-e561.

Attard, G., de Bono, J.S., Clark, J. & Cooper, C.S. (2010). Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies. Clin cancer res, Vol.16 (4), p. 1340.

Reid, A.H., Attard, G., Ambroisine, L., Fisher, G., Kovacs, G., Brewer, D., Clark, J., Flohr, P., Edwards, S., Berney, D.M., et al. (2010). Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br j cancer, Vol.102 (4), pp. 678-684.  show abstract

Reid, A.H., Attard, G., Danila, D.C., Oommen, N.B., Olmos, D., Fong, P.C., Molife, L.R., Hunt, J., Messiou, C., Parker, C., et al. (2010). Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J clin oncol, Vol.28 (9), pp. 1489-1495.  show abstract

Attard, G., Swennenhuis, J., Olmos, D., Reid, A., Coumans, F., Vickers, E., Oommen, N.B., Thompson, E., A'Hern, R., Cox, M., et al. (2009). Molecular characterization of circulating tumor cells (CTC) from castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA). Cancer research, Vol.69.

Attard, G., Swennenhuis, J., Olmos, D., Reid, A., Coumans, F., Vickers, E., Oommen, N.B., Thompson, E., A'Hern, R., Cox, M., et al. (2009). Molecular characterization of circulating tumor cells (CTC) from castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA). Cancer research, Vol.69.

Attard, G., Swennenhuis, J., Olmos, D., Reid, A., Coumans, F., Vickers, E., Oommen, N.B., Thompson, E., A'Hern, R., Cox, M., et al. (2009). Molecular characterization of circulating tumor cells (CTC) from castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA). Cancer research, Vol.69.

Olmos, D., Arkenau, H.-., Ang, J.E., Ledaki, I., Attard, G., Carden, C.P., Reid, A.H., A'Hern, R., Fong, P.C., Oomen, N.B., et al. (2009). Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann oncol, Vol.20 (1), pp. 27-33.  show abstract

Attard, G., Rizzo, S., Ledaki, I., Clark, J., Reid, A.H., Thompson, A., Khoo, V., de Bono, J.S., Cooper, C.S. & Hudson, D.L., et al. (2009). A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies. Prostate, Vol.69 (14), pp. 1507-1520.  show abstract

Reid, A.H., Protheroe, A., Attard, G., Hayward, N., Vidal, L., Spicer, J., Shaw, H.M., Bone, E.A., Carter, J., Hooftman, L., et al. (2009). A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. Clin cancer res, Vol.15 (15), pp. 4978-4985.  show abstract

Attard, G., Swennenhuis, J.F., Olmos, D., Reid, A.H., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009). Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer res, Vol.69 (7), pp. 2912-2918.  show abstract

Attard, G., Jameson, C., Moreira, J., Flohr, P., Parker, C., Dearnaley, D., Cooper, C.S. & de Bono, J.S. (2009). Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. J clin pathol, Vol.62 (4), pp. 373-376.  show abstract

Jhavar, S., Brewer, D., Edwards, S., Kote-Jarai, Z., Attard, G., Clark, J., Flohr, P., Christmas, T., Thompson, A., Parker, M., et al. (2009). Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. Bju int, Vol.103 (9), pp. 1256-1269.  show abstract

Attard, G., Cooper, C.S. & de Bono, J.S. (2009). Steroid hormone receptors in prostate cancer: a hard habit to break?. Cancer cell, Vol.16 (6), pp. 458-462.  show abstract

Attard, G. & de Bono, J.S. (2009). Prostate cancer: PSA as an intermediate end point in clinical trials. Nat rev urol, Vol.6 (9), pp. 473-475.

Attard, G., Reid, A.H., A'Hern, R., Parker, C., Oommen, N.B., Folkerd, E., Messiou, C., Molife, L.R., Maier, G., Thompson, E., et al. (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J clin oncol, Vol.27 (23), pp. 3742-3748.  show abstract

Attard, G., Reid, A.H., Olmos, D. & de Bono, J.S. (2009). Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer res, Vol.69 (12), pp. 4937-4940.  show abstract

Reid, A.H., Attard, G., Danila, D., Ryan, C.J., Thompson, E., Kheoh, T., Molina, A., Small, E., Scher, H. & De-Bono, J.S., et al. (2009). A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J clin oncol, Vol.27 (15_suppl), p. 5047.  show abstract

Foster, C.S., Dodson, A.R., Ambroisine, L., Fisher, G., Moller, H., Clark, J., Attard, G., De-Bono, J., Scardino, P., Reuter, V.E., et al. (2009). Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Brit j cancer, Vol.101 (7), pp. 1137-1144.  show abstract

Attard, G., Reid, A.H., Yap, T.A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J clin oncol, Vol.26 (28), pp. 4563-4571.  show abstract

Attard, G., Ang, J.E., Olmos, D. & de Bono, J.S. (2008). Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. J clin pathol, Vol.61 (8), pp. 891-896.  show abstract

Yap, T.A., Carden, C.P., Attard, G. & de Bono, J.S. (2008). Targeting CYP17: established and novel approaches in prostate cancer. Curr opin pharmacol, Vol.8 (4), pp. 449-457.  show abstract

Attard, G., Clark, J., Ambroisine, L., Fisher, G., Kovacs, G., Flohr, P., Berney, D., Foster, C.S., Fletcher, A., Gerald, W.L., et al. (2008). Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene, Vol.27 (3), pp. 253-263.  show abstract

Attard, G., Reid, A.H., Dearnaley, D. & De Bono, J.S. (2008). New prostate cancer drug: Prostate cancer's day in the sun. Bmj, Vol.337, p. a1249.

Reid, A.H., Attard, G., Barrie, E. & de Bono, J.S. (2008). CYP17 inhibition as a hormonal strategy for prostate cancer. Nat clin pract urol, Vol.5 (11), pp. 610-620.  show abstract

Shepherd, C.J., Rizzo, S., Ledaki, I., Davies, M., Brewer, D., Attard, G., de Bono, J. & Hudson, D.L. (2008). Expression profiling of CD133+ and CD133- epithelial cells from human prostate. Prostate, Vol.68 (9), pp. 1007-1024.  show abstract

Attard, G., Olmos, D., Arkenau, H.T., Ledaki, I., Carden, C.P., Reid, A.H., Ang, J., Fong, P.C., Parker, C. & De Bono, J.S., et al. (2008). Pre- and post-treatment circulating tumor cell counts (CTCc) and overall survival (OS) in castration-resistant prostate cancer (CRPC): The Royal Marsden Hospital (RMH) experience. Journal of clinical oncology, Vol.26 (15).

De Bono, J.S., Attard, G., Reid, A.H., Parker, C., Dowsett, M., Mollife, R., Yap, T.A., Molina, A., Lee, G. & Dearnaley, D., et al. (2008). Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). Journal of clinical oncology, Vol.26 (15).

Attard, G., Clark, J., Ambroisine, L., Mills, I.G., Fisher, G., Flohr, P., Reid, A., Edwards, S., Kovacs, G., Berney, D., et al. (2008). Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br j cancer, Vol.99 (2), pp. 314-320.  show abstract

Clark, J., Attard, G., Jhavar, S., Flohr, P., Reid, A., De-Bono, J., Eeles, R., Scardino, P., Cuzick, J., Fisher, G., et al. (2008). Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene, Vol.27 (14), pp. 1993-2003.  show abstract

Clark, J., Attard, G., Ambroisine, L., Mills, I.G., Fisher, G., Flohr, P., Reid, A., Edwards, S., Kovacs, G., Berney, D., et al. (2008). ETS GENE TRANSLOCATIONS AND PROSTATE CANCER PROGNOSIS. Anticancer research, Vol.28 (6B), pp. 4155-4156.

Attard, G. & De Bono, J.S. (2007). Targeting human epidermal growth factor receptor 2: It is time to kill kinase death human epidermal growth factor receptor 3 - Reply. J clin oncol, Vol.25 (17), pp. 2499-2499.

Attard, G., Reid, A.H., Sinha, R., Molife, R., Raynaud, F., Dowsett, M., Barrett, M., Thompson, E., Yap, T.A., Settatree, S., et al. (2007). Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC). Mol cancer ther, Vol.6 (12), pp. 3455S-3455S.

Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N.L., et al. (2007). Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin cancer res, Vol.13 (20), pp. 6187-6194.  show abstract

de Bono, J.S., Attard, G., Adjei, A., Pollak, M.N., Fong, P.C., Haluska, P., Roberts, L., Melvin, C., Repollet, M., Chianese, D., et al. (2007). Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin cancer res, Vol.13 (12), pp. 3611-3616.  show abstract

Attard, G., Kitzen, J., Blagden, S.P., Fong, P.C., Pronk, L.C., Zhi, J., Zugmaier, G., Verweij, J., de Bono, J.S. & de Jonge, M., et al. (2007). A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br j cancer, Vol.97 (10), pp. 1338-1343.  show abstract

de Bono, J.S., Bellmunt, J., Attard, G., Droz, J.P., Miller, K., Flechon, A., Sternberg, C., Parker, C., Zugmaier, G., Hersberger-Gimenez, V., et al. (2007). Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J clin oncol, Vol.25 (3), pp. 257-262.  show abstract

Attard, G., De Bono, J.S., Parker, C. & Horwich, A. (2006). Management strategies for hormone-refractory prostate cancer. American journal of cancer, Vol.5 (3), pp. 163-169.

Agius, E., Attard, G., Shakespeare, L., Clark, P., Vidya, M.-., Hattersley, A.T. & Fava, S. (2006). Familial factors in diabetic nephropathy: an offspring study. Diabet med, Vol.23 (3), pp. 331-334.  show abstract

Attard, G., Greystoke, A., Kaye, S. & De Bono, J. (2006). Update on tubulin-binding agents. Pathol biol (paris), Vol.54 (2), pp. 72-84.  show abstract

Greystoke, A., Blagden, S., Thomas, A.L., Scott, E., Attard, G., Molife, R., Vidal, L., Pacey, S., Sarkar, D., Jenner, A., et al. (2006). A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. Ann oncol, Vol.17 (8), pp. 1313-1319.  show abstract

Attard, G., Sarker, D., Reid, A., Molife, R., Parker, C. & de Bono, J.S. (2006). Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br j cancer, Vol.95 (7), pp. 767-774.  show abstract

Fong, P.C., Molife, R.L., Spicer, J., Yap, T.A., Settatree, S., Digue, L., Attard, G., Karavasilis, V., Gualberto, A. & de Bono, J.S., et al. (2006). A phase I trial incorporating the pharmacodynamic (PD) study of circulating tumour cells (CTC) of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), in combination with docetaxel (D) in patients (p) with advanced cancer. Ejc suppl, Vol.4 (12), pp. 61-62.

Lee, C.P., Taylor, N.J., Attard, G., Nathan, P.D., De Bono, J.S., Temple, G., Tang, A., Padhani, A.R., Judson, I.R. & Rustin, G.J., et al. (2006). A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Journal of clinical oncology, Vol.24 (18), pp. 124S-124S.

Attard, G., Fong, P.C., Molife, R., Reade, S., Shaw, H., Reid, A., Spicer, J., Hamlin, J., Gualberto, A. & De Bono, J.S., et al. (2006). Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer. Journal of clinical oncology, Vol.24 (18), pp. 126S-126S.

Reid, A., Protheroe, A., Attard, G., Cowsill, C., Spicer, J., Vidal, L., Bone, E., Hooftman, L., Harris, A. & De-Bono, J.S., et al. (2006). A phase 1 dose finding study of CHR-2797, an inhibitor of M1 aminopeptidases, in patients with advanced solid tumours. Journal of clinical oncology, Vol.24 (18), pp. 134S-134S.

Pacey, S., Plummer, R.E., Attard, G., Bale, C., Calvert, A.H., Blagden, S., Fox, N.L., Corey, A. & de Bono, J.S. (2005). Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies. Journal of clinical oncology, Vol.23 (16), pp. 205S-205S.

Blagden, S., Thomas, A., De-Bono, J.S., Ahmed, S., Greystoke, A., Attard, G., Jenner, A., Fong, P. & Steward, W.P. (2005). Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on Day 1 (T and C) and Day 8 (T) every three weeks in patients (pts) with advanced solid tumors. Journal of clinical oncology, Vol.23 (16), pp. 226S-226S.

Steele, N., Vidal, L., Plumb, J., Attard, G., Rasmussen, A., Buhl-Jensen, P., Brown, R., Blagden, S., Evans, J. & de Bono, J., et al. (2005). A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours. Journal of clinical oncology, Vol.23 (16), pp. 200S-200S.

Lee, C.P., Attard, G., Poupard, L., Nathan, P.D., de Bono, J.S., Temple, G.M., Stefanic, M.F., Padhani, A.R., Judson, I.R. & Rustin, G.J., et al. (2005). A phase I study of BIBF 1120, an orally active triple angiolkinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. Journal of clinical oncology, Vol.23 (16), pp. 205S-205S.

Attard, G., Kitzen, J.J., de Bono, J., Verweij, J., Pronk, L., Zhi, J., Blagden, S.P., Reade, S.E., Zugmaier, G. & de Jonge, M.J., et al. (2005). A phase 1b study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors. Journal of clinical oncology, Vol.23 (16), pp. 232S-232S.

Rizzo, S., Attard, G. & Hudson, D.L. (2005). Prostate epithelial stem cells. Cell prolif, Vol.38 (6), pp. 363-374.  show abstract

Attard, G., Belldegrun, A.S. & de Bono, J.S. (2005). Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. Bju int, Vol.96 (9), pp. 1241-1246.

(2004). Bulletin Board. Therapy, Vol.1 (1), pp. 7-10.

Dearnaley, D.P., Ottensmeier, C., Attard, G. & Crabb, S. New horizons for prostate cancer: part 1. Trends in urology and men's health, , pp. Reports 1-3.

Vidal, L., Attard, G., Kaye, S. & De Bono, J.S. Reversing Resistance To Targeted Therapy. J chemother 2004, (S4), pp. 7-12.

Vidal, L., Blagden, S., Attard, G. & De Bono, J.S. Making Sense of antisense. Eur j cancer 2005, (41), pp. 2812-2818.


Conferences

Sharabiani, M., Peckitt, C. & Attard, G. (2017). Log-likelihood is the best correlative measure to estimate the cutpoint for a continuous prognostic variable: a Monte Carlo simulation, TRIALS, Vol.18.

Lozano Mejorada, R., Romero Laorden, N., Jayaram, A., Lopez, F., Saez, M.I., Villatoro, R., Montesa, A., Moreno, I., Ruiz Vico, M., Garcia Ferron, M., et al. (2017). Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA plus P), ANNALS OF ONCOLOGY, Vol.28.

Conteduca, V., Salvi, S., Caroli, P., Scarpi, E., Schepisi, G., Lolli, C., Wetterskog, D., Burgio, S.L., Menna, C., Casadio, V., et al. (2017). Combining functional imaging with circulating biomarker analysis to improve prognostication of metastatic castration-resistant prostate cancer (mCRPC), ANNALS OF ONCOLOGY, Vol.28.

Attard, G., Merseburger, A.S., Sternberg, C.N., Cerbone, L., Recine, F., Jones, R.J., Feyerabend, S., Berruti, A., Joniau, S., Schatteman, P., et al. (2016). A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)., JOURNAL OF CLINICAL ONCOLOGY, Vol.34 (2).

Posadas, E.M., Chit, K.N., de Wit, R., de Jonge, M.J., Attard, G., Friedlander, T., Yu, M., Hellemans, P., Chien, C., Abrams, C., et al. (2015). Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), CANCER RESEARCH, Vol.75.

Conteduca, V., Salvi, S., Caroli, P., Scarpi, E., Lolli, C., Burgio, S.L., Menna, C., Schepisi, G., Bianchi, E., Gurioli, G., et al. (2015). The correlation between circulating cell-free AR and CYP17A1 copy number variations and tumor burden estimated by 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone, EUROPEAN JOURNAL OF CANCER, Vol.51, pp.S503-S504.

Attard, G., Gurney, H., Loriot, Y., Borre, M., Andresen, C., Wu, K., Taylor, C., Amelsberg, A. & Taplin, M.E. (2015). Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), EUROPEAN JOURNAL OF CANCER, Vol.51, p.S487.

Posadas, E.M., Chi, K.N., De Wit, R., De Jonge, M.J., Attard, G., Friedlander, T.W., Yu, M.K., Hellemans, P., Chien, C., Abrams, C.C., et al. (2015). Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Montgomery, R.B., Antonarakis, E.S., Hussain, M., Fizazi, K., Joshua, A.M., Attard, G., Sadar, M., Perabo, F. & Chi, K.N. (2015). A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Rathkopf, D.E., Attard, G., Efstathiou, E., Yu, M.K., Griffin, T.W., Todd, M.B., Wu, D., Kheoh, T., Zhao, X. & Saad, F., et al. (2015). A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)., JOURNAL OF CLINICAL ONCOLOGY, Vol.33 (15).

Attard, G. (2010). IMPROVED INHIBITION OF THE ANDROGEN RECEPTOR, ANNALS OF ONCOLOGY, Vol.21, p.29.

Benepal, T., Attard, G., Johnston, S.R. & Smith, I.E. (2004). Navelbine (N-v) and trastuzumab (T-R) in combination for advanced breast cancer: A retrospective single institution analysis, BRITISH JOURNAL OF CANCER, Vol.91, p.S25.

In this section

Publications